Stifel Maintains Buy on DexCom, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman maintains a Buy rating on DexCom (NASDAQ:DXCM) but lowers the price target from $132 to $90.
July 26, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stifel analyst Mathew Blackman maintains a Buy rating on DexCom but lowers the price target from $132 to $90.
The Buy rating suggests continued confidence in DexCom's long-term prospects, but the lowered price target indicates potential short-term challenges or adjustments in valuation expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100